


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Ascension Standish Hospital</p> <p>2. 805 W Cedar St. Standish, MI 48658</p>	<p>In accordance with letter dated April 20, 2022,</p>	<p>4. Expiration Date: May 31, 2024</p>
	<p>3. License No.: 21-21265-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-20121 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p>



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-21265-01

Docket or Reference No.:  
030-20121

Amendment No. 24

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 805 W Cedar St., Standish, Michigan, 48658.
11. The Radiation Safety Officer (RSO) for this license is Cynthia Blount, D.O.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Macksood A. Aftab, D.O.	10 CFR 35.100,10 CFR 35.200
Sarosh Anwar, M.D.	10 CFR 35.100,10 CFR 35.200
Cynthia Blount, D.O.	10 CFR 35.100,10 CFR 35.200
Jeffery W. Carney, M.D.	10 CFR 35.100,10 CFR 35.200
Ahmed Mohamed M El-Sabbagh, M.D.	10 CFR 35.100,10 CFR 35.200
Roger L. Gonda, Jr., M.D.	10 CFR 35.100,10 CFR 35.200
Karl F. Kado, M.D.	10 CFR 35.100,10 CFR 35.200
Vikram Aroor Kinni, M.D.	10 CFR 35.100,10 CFR 35.200
Steve Min, D.O.	10 CFR 35.100,10 CFR 35.200
Nishtha Sareen, M.D.	10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**


License No.: 21-21265-01

Docket or Reference No.:  
030-20121

Amendment No. 24

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated December 16, 2013 (ML13360A088)
- B. Letter dated May 22, 2014 (ML14161A505)
- C. Letter dated July 24, 2014 (ML14211A400)
- D. Letter dated May 26, 2015 (ML15174A305)
- E. Letter dated November 28, 2020, limited to RSO change to Dr. Blount (ML21034A416)
- F. Letter dated January 20, 2022 (ML22020A269)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: October 13, 2022By: \_\_\_\_\_  
Magdalena R. Gryglak  
Region 3